​Meet the Scientist behind FissionBio

​Meet the Scientists
🗓️ June 4th · 6:00 PM CET (Berlin)

​Join us for a live conversation with leading scientists pioneering a new class of small molecules to treat neurodegenerative disease. Fission Bio is developing the first drug-like mimetics of P110—a mito-protective peptide discovered at Stanford—that target chronic inflammation and mitochondrial dysfunction without suppressing the immune system. Early results in ALS and other models show promising potential.

​🔬 Speakers:

• ​Brian Magierski – Founding Steward, Cerebrum DAO

• ​Luis Rios, PhD – Co-founder, Fission Bio

​💡 About Fission Bio
Backed by 13 years of research across 11 disease models and 20 publications, P110 has shown strong efficacy in neurodegenerative and cardiac disease. In 2023, Dr. Luis Rios published the first small-molecule versions of P110, which match its effectiveness in ALS and sepsis models. These orally available, brain-penetrant compounds may offer a safe, generalized treatment for inflammation-driven diseases like ALS and Alzheimer’s—without the risk of immunosuppression.

​
How to participate?
Enter our studio on https://streamyard.com/g5t76rv7n9
View on Youtube: https://www.youtube.com/@cerebrumdao/streams
Or on X/Twitter: https://x.com/cerebrum_dao